<DOC>
	<DOCNO>NCT02245568</DOCNO>
	<brief_summary>The purpose study provide subject complete participation Phase 2 Phase 3 trial TRx0237 continue access therapy evaluate long-term safety TRx0237 .</brief_summary>
	<brief_title>Open-Label Study TRx0237 Subjects With Alzheimer 's Disease Behavioral Variant Frontotemporal Dementia ( bvFTD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<criteria>Subjects cause dementia probable Alzheimer 's disease enrollment complete participation one follow three TauRx study ( inclusive 4week posttreatment followup visit ) : TRx237005 , TRx237008 , TRx237015 . Subjects diagnosis probable bvFTD enrollment complete participation TauRx study TRx237007 Visit 9 ( Week 52 ) . Females , childbearing potential , must practice true abstinence continue use adequate contraception agree maintain throughout study Subject , and/or , case reduce decisionmaking capacity , legally acceptable representative ( ) consistent national law ethic approval is/are able read , understand , provide write informed consent Has identify adult caregiver willing provide write informed consent his/her participation ; able read , understand , speak designate language study site ; either live subject see subject ≥1 hour/day ≥3 days/week ; agree accompany subject study visit ; able verify daily compliance study drug Able comply study procedure History swallow difficulty Pregnant breastfeed Clinically significant laboratory , pulse cooximetry , electrocardiogram , image abnormality ( originate study ) emergent intercurrent illness , judgment principal investigator , could result risk participation outweigh potential benefit Current participation , intent enroll , another clinical trial drug , biologic , device , medical food In Germany , subject mandate reside continuous care assist living facility whose willingness participate clinical trial may unduly influenced</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer Disease</keyword>
	<keyword>bvFTD</keyword>
	<keyword>Frontotemporal Dementia</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Cognitive Disorders</keyword>
</DOC>